Executing Plan to File NDA for Durasert Three-year Treatment for Posterior Segment Uveitis

Conference Call and Webcast Today, September 11th, at 4:30 p.m. ET

WATERTOWN, Mass., Sept. 11, 2017 (GLOBE NEWSWIRE) -- pSivida Corp. (NASDAQ:PSDV) (ASX:PVA), a leader in the development of sustained release drug products and technologies, today reported financial results for its fiscal 2017 fourth quarter and full year ended June 30, 2017.  The Company achieved several significant milestones during FY 2017 and has built operational, clinical and business development momentum entering FY 2018.

Recent Operating Highlights
  • Reported that data from the second Phase 3 trial of Durasert™ three-year treatment for posterior segment uveitis achieved its primary endpoint. The results demonstrated a significant reduction in the recurrence of posterior segment uveitis through six months: 21.8% of Durasert-treated patients had a recurrence compared to 53.8% of patients in the sham group (p < 0.001).
  • Successfully completed a pre-NDA meeting with the FDA for Durasert three-year uveitis that included FDA's agreement with pSivida's proposed overall clinical data package. The Company expects to file the NDA in late December or early January.
  • Leading retina specialists presented data for the first Phase 3 trial of Durasert at recent medical conferences: the EURETINA Congress and annual meetings of the Association for Research in Vision and Ophthalmology (ARVO) and the American Society of Retinal Specialists (ASRS).
  • Amended the existing collaboration agreement for ILUVIEN ® to change the payment terms to a net sales royalty paid to pSivida, resulting in improved financial terms for the Company, and to grant regulatory and commercial rights to Durasert three-year uveitis in Europe, the Middle East and Africa (EMEA).
  • Hospital for Special Surgery (HSS) completed enrollment in an investigator-sponsored Phase 1 study to evaluate safety and the effect on pain and function of a combination product including Durasert technology providing sustained delivery of dexamethasone for the management of osteoarthritic knees. 

"We achieved all of our key objectives during fiscal 2017 and have made great strides towards becoming a fully integrated pharmaceutical company," commented Nancy Lurker, President and Chief Executive Officer. "Consistent with our first Phase 3 clinical trial, our second Phase 3 study of Durasert three-year treatment in posterior segment uveitis achieved its primary efficacy endpoint, and we are implementing our plan to file an NDA with the FDA by late December or early January 2018. Based on the prior regulatory approvals for Durasert's three sustained-release treatments for back-of-the-eye diseases utilizing the same core technology, we are optimistic about the regulatory review process for the product and continue to prepare for a direct commercialization effort in the U.S."

Fiscal Fourth Quarter and Full Year 2017 Results

Revenue for the fourth fiscal quarter ended June 30, 2017 totaled $701,000 compared to $304,000 for the prior year quarter. Operating expenses totaled $6.8 million for each of the three-month periods ended June 30, 2017 and 2016. Net loss for the quarter ended June 30, 2017 was $6.1 million, or $0.16 per share compared to a net loss of $6.4 million, or $0.19 per share, for the prior year quarter.

Revenue for the full year ended June 30, 2017 was $7.5 million compared to $1.6 million for the full year ended June 30, 2016. The year-over-year increase was primarily attributable to the $5.6 million of revenue recognized (in the fiscal second quarter) upon termination of the Pfizer agreement.  Net loss for the year ended June 30, 2017 was $18.5 million, or $0.52 per share compared to a net loss of $21.5 million, or $0.68 per share, for the corresponding fiscal year ended June 30, 2016.

During the fiscal 2017 fourth quarter, the Company issued approximately 3.7 million shares of common stock for gross proceeds of $6.4 million through utilization of its existing at-the-market (ATM) equity offering program.  At June 30, 2017, the Company's cash and cash equivalents totaled $16.9 million.

Anticipated FY2018 milestones:
  • File Durasert three-year uveitis NDA in the U.S. in late December 2017/early January 2018.
  • Announce 12-month read-out of Durasert three-year uveitis efficacy and safety results for the second Phase 3 clinical trial.
  • Present clinical study data at leading medical conferences, including the American Academy of Ophthalmology (AAO) annual meeting.
  • Progress Durasert shorter duration uveitis through submission-enabling pre-clinical studies.
  • Finalize additional collaboration agreements with biopharmaceutical companies and other third parties.
  • Report the initial 24-week data for the Phase 1 trial of knee osteoarthritis (OA).

Conference Call

pSivida Corp. will host a live webcast and conference call today, September 11th, at 4:30pm ET. The conference call may be accessed by dialing (877) 312-7507 from the U.S. and Canada, or (631) 813-4828 from international locations. The conference ID is 80833777. A live webcast will be available on the Investor Relations section of the corporate website at http://www.psivida.com.

A replay of the call will be available beginning September 11, 2017 at approximately 7:30 p.m. ET and ending on September 18, 2017 at 11:59 p.m. ET. The replay may be accessed by dialing (855) 859-2056 within the U.S. and Canada or (404) 537-3406 from international locations, Conference ID Number: 80833777. A replay of the webcast will also be available on the corporate website during that time.

About pSivida Corp.

pSivida Corp. ( www.psivida.com), headquartered in Watertown, MA, is a leader in the development of sustained release drug products for treating eye diseases. pSivida has developed three of only four FDA-approved sustained-release treatments for back-of-the-eye diseases. The most recent, ILUVIEN ®, a micro-insert for diabetic macular edema, licensed to Alimera Sciences, is currently sold directly in the U.S. and three EU countries. Retisert ®, an implant for posterior uveitis, is licensed to and sold by Bausch & Lomb. pSivida's lead product candidate, Durasert™ micro-insert for posterior segment uveitis, is being independently developed. Two pivotal Phase 3 studies with Durasert achieved their primary efficacy endpoint of prevention of recurrence of uveitis at six months of follow-up with statistical significance, and the Company plans to file an NDA by late December 2017/early January 2018. pSivida's pre-clinical development program is focused on using its core platform technology Durasert™ to deliver drugs to treat wet age-related macular degeneration, glaucoma, osteoarthritis and other diseases. To learn more about pSivida, please visit  www.psivida.com and connect on Twitter, LinkedIn, Facebook and Google+.

SAFE HARBOR STATEMENTS UNDER THE PRIVATE SECURITIES LITIGATION REFORM ACT OF 1995: Various statements made in this release are forward-looking, and are inherently subject to risks, uncertainties and potentially inaccurate assumptions. All statements that address activities, events or developments that we intend, expect or believe may occur in the future are forward-looking statements. Some of the factors that could cause actual results to differ materially from the anticipated results or other expectations expressed, anticipated or implied in our forward-looking statements include uncertainties with respect to: our ability to achieve profitable operations and access to needed capital; fluctuations in our operating results; successful commercialization of, and receipt of revenues from, ILUVIEN® for diabetic macular edema ("DME"), which depends on Alimera's ability to continue as a going concern and the effect of pricing and reimbursement decisions on sales of ILUVIEN; the successful development and, if approved, commercialization of Durasert (under the ILUVIEN trademark) for posterior segment uveitis in Europe, the Middle East and Africa ("EMEA") by Alimera; the number of clinical trials and data required for the Durasert three-year uveitis marketing approval applications in the U.S. and EU; our ability to file and the timing of filing and acceptance of the Durasert three-year uveitis marketing approval applications in the U.S.; our ability to use data in a U.S. NDA from clinical trials outside the U.S.; our ability to successfully commercialize Durasert three-year uveitis, if approved; potential off-label sales of ILUVIEN for uveitis; consequences of fluocinolone acetonide side effects; potential declines in Retisert® royalties; efficacy and our future development of an implant to treat severe osteoarthritis; our ability to successfully develop product candidates, initiate and complete clinical trials and receive regulatory approvals; our ability to market and sell products; the success of current and future license agreements, including our agreement with Alimera; termination or breach of current license agreements, including our agreement with Alimera; our dependence on contract research organizations, vendors and investigators; effects of competition and other developments affecting sales of products; market acceptance of products; effects of guidelines, recommendations and studies; protection of intellectual property and avoiding intellectual property infringement; retention of key personnel; product liability; industry consolidation; compliance with environmental laws; manufacturing risks; risks and costs of international business operations; effects of the potential U.K. exit from the EU; legislative or regulatory changes; volatility of stock price; possible dilution; absence of dividends; and other factors described in our filings with the Securities and Exchange Commission. You should read and interpret any forward-looking statements in light of these risks. Should known or unknown risks materialize, or should underlying assumptions prove inaccurate, actual results could differ materially from past results and those anticipated, estimated or projected in the forward-looking statements. You should bear this in mind as you consider any forward-looking statements. Our forward-looking statements speak only as of the dates on which they are made. We do not undertake any obligation to publicly update or revise our forward-looking statements even if experience or future changes makes it clear that any projected results expressed or implied in such statements will not be realized.
  (In thousands, except per share amounts)
          Three Months Ended     Year Ended
          June 30,     June 30,
            2017       2016         2017       2016  
    Collaborative research and development   $ 461     $ 26       $ 6,569     $ 398  
    Royalty income     240       278         970       1,222  
      Total revenues     701       304         7,539       1,620  
  Operating expenses:                  
    Research and development     4,213       4,104         14,880       14,381  
    General and administrative     2,624       2,656         11,235       9,013  
      Total operating expenses     6,837       6,760         26,115       23,394  
  Loss from operations     (6,136 )     (6,456 )       (18,576 )     (21,774 )
  Interest and other income     20       31         91       72  
  Loss before income taxes     (6,116 )     (6,425 )       (18,485 )     (21,702 )
  Income tax benefit     -       38         -       155  
  Net loss   $ (6,116 )   $ (6,387 )     $ (18,485 )   $ (21,547 )
  Net loss per common share:                  
    Basic and diluted   $ (0.16 )   $ (0.19 )     $ (0.52 )   $ (0.68 )
  Weighted average common shares outstanding:                
    Basic and diluted     38,673       34,152         35,344       31,623  

  (In thousands)  
          June 30,   June 30,  
            2017       2016    
  Current assets:          
    Cash, cash equivalents and marketable securities $ 16,898     $ 28,992    
    Other current assets   842       971    
  Total current assets   17,740       29,963    
  Intangible assets, net   364       1,102    
  Other assets     573       554    
  Total assets   $ 18,677     $ 31,619    
  Liabilities and stockholders' equity        
  Current liabilities:        
    Accounts payable and accrued expenses $ 5,240     $ 4,946    
    Deferred revenue   50       147    
  Total current liabilities   5,290       5,093    
  Deferred revenue   -       5,585    
  Deferred rent     51       60    
  Total liabilities     5,341       10,738    
  Stockholders' equity:        
    Capital   323,323       312,242    
    Accumulated deficit   (310,820 )     (292,213 )  
    Accumulated other comprehensive income   833       852    
  Total stockholders' equity   13,336       20,881    
  Total liabilities and stockholders' equity $ 18,677     $ 31,619    
Contact:EVC GroupMichael Polyviou/Doug Sherk - Investorsmpolyviou@evcgroup.com; dsherk@evcgroup.com212.850.6020; 646-445-4800Thomas Gibson - Mediatom@tomgibsoncommunications.com201-476-0322

Primary Logo